Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1

Interventions

Sorafenib 23Bevacizumab 11Radiosurgery 6Capecitabine 6Radiofrequency Ablation 5Oxaliplatin 5Fluorouracil 5Doxorubicin 5pembrolizumab 4Sunitinib 4Erlotinib Hydrochloride 4Cisplatin 4Ramucirumab 3Radiotherapy 3Nivolumab 3Leucovorin 3Carboplatin 3tremelimumab 2spartalizumab 2perflutren 2derazantinib 2carotuximab 2Mitomycin 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Immunohistochemistry 2Gemcitabine 2Folfox protocol 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liver Neoplasms × bavituximab × Clear all
NCT01264705 2020-11-12

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Completed
47 enrolled 10 charts
Gastrointestinal

Fibrosis, Gastrointestinal Neoplasms, Hepatitis, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡